The design of pharmaceutical facilities is much more than an architectural exercise: it constitutes The basis for guaranteeing product quality, the patient safety and the regulatory compliance.
Given the complexity of the topic, we have divided this article into two parts. In this first installment we will address the essential foundations of the design under GMP, those principles that feel the basis of any solid pharmaceutical project. In the second part, we will deepen the advanced aspects, current challenges and trends that are transforming the industry.
Separate and controlled flows
One of the pillars in the design of pharmaceutical facilities is to ensure that personnel flows, raw materials, product in process, finished product and finished product are clearly defined, separated and controlled. This strategy seeks to minimize the risk of cross contamination, maintain product integrity and ensure traceability at each stage of the process.
Personnel flow
Access must be designed with Watercress costumes, which allows a progressive change of clothing based on the degree of cleaning of the area to which it is accessed. This approach guarantees that Every step of the clothing process Reduce particle load and Microorganisms that can be introduced in critical areas.
Likewise, the circulation of the personnel must be considered as Unidirectional, avoiding setbacks that compromise the classification of the areas and increase the risk of cross contamination. A well -defined design of traffic routes helps maintain the integrity of controlled environments and facilitate the traceability of movements within the installation.
On the other hand, the design must contemplate LEVELS WITH DIFFERENTIAL PRESSURE CONTROL and Clear entry and exit procedures. These locks act as physical and environmental barriers that reinforce the separation between areas with different classification, guaranteeing that air always flows from cleaner areas to the least clean.
Flow of materials and products
Mechanisms that guarantee the safe traffic of materials and products should be established without interfering with the movement of personnel. To do this, the use of airlocks or material locks It is necessary, since they act as controlled transfer points and avoid the introduction of pollutants when passing from one area to another.
In addition, the design must contemplate Differentiated routes for each product category: raw materials, product in process, finished product and finished product. This segregation not only minimizes the risk of cross contamination, but also facilitates traceability and compliance with regulatory guidelines.
The systems of automated transportation, as automatic guided vehicles (AGVs) the transporters (conveyors), represent an effective tool to maintain flow separation. These systems reduce manual intervention, increase operational efficiency and provide a higher level of control in the transfer of materials within the plant.
Waste management
Waste management is another aspect to have in design, since its circulation and withdrawal They must be performed totally SECREGED OF THE FLOW OF MATERIALS AND PRODUCTS. This separation is key to avoiding any possibility of cross contamination and ensuring that waste does not compromise the quality of productive areas.
Plant design must foresee Specific circuits for waste evacuation, ideally towards external technical areas that allow collection and treatment without interfering with production operations. This approach not only reduces contamination risks, especially improves efficiency in cleaning and control tasks.
It is also very important to establish validated manipulation and withdrawal protocols that define how they are transported, temporarily stored and eliminated the different types of waste, whether solid, liquid or biological, always in accordance with current environmental and health regulations.
CRITALS AND CRITICAL POINTS
These represent one of the main critical risk points. Ideally, they are completely eliminated in the design phase, through adequate planning of corridors, locks and differentiated routes. However, when these crosses are inevitable for space or functionality limitations, it is necessary to implement additional control measures.
These measures include the physical barriers that prevent direct contact between personnel and material flows, as well as the Establishment of differential pressure systems that direct clean air from critical areas to areas of lower classification, thus reducing the risk of dragging particles or microorganisms.
On the other hand, you can Define standardized operational procedures (SOPs) that regulate sequence and passage times in crossing areas, guaranteeing that different flows do not coincide simultaneously. These practices, combined with architectural design and HVAC system support, reinforce the safety of operations and minimize the risks associated with cross contamination.
Integration with HVAC systems
These systems not only control temperature and humidity, but also They ensure that the air movement follows predefined patterns that support the separation between classified areas.
One of the most effective mechanisms is Pressure waterfall implementation, which allow air to flow from clean areas to less critical areas. In this way, the entry of contaminants in high control areas is avoided, guaranteeing that environmental conditions remain stable and aligned with the GMP requirements.
In addition, the HVAC system should be designed to maintain differential pressure gradients, adjusted to the criticality of each area, and complement with a robust HEPA filtration system, capable of eliminating particles and microorganisms in suspension. This combination reinforces the physical separation of personnel flows, materials and residuity, reducing the possibility of cross contamination.
Finally, it is essential to implement a continuous monitoring program of critical variables As pressure, flow and particles, with alarms that alert in real time before any deviation. This integration between architecture, operations and air conditioning systems constitutes the basis of a controlled, validated and safe environment for pharmaceutical production.
Contamination control
In the design of facilities under GMP, the contamination control is achieved through a combination of architecture, air conditioning systems (HVAC), Construction materials, air flows, Differential pressure and operational practices.
Classification of clean areas
The classification of clean areas must be established following the guidelines of ISO 14644 and Annex 1 of the EU GMP, which define the cleaning degrees (A, B, C and D) depending on the maximum concentration of particles allowed in the air.
It is important that this classification contemplates both the "at rest" conditions, that is, when the facilities are prepared but without operational activity, such as "in operation" conditions, where staff, equipment and processes are in operation, since only in this way it is ensured that the environment meets the requirements in real production scenarios.
HVAC system design
The HVAC system design in pharmaceutical installations must contemplate the installation of high efficiency HEPA filters (H13/H14) for guarantee a clean and particle -free air supply, accompanied by strict control of differential pressures between areas with different classification, which allows the air flow to be controlled in a controlled way. To this is added the Precise temperature and humidity regulation, factors that not only provide operational comfort, but are basic to prevent conditions favorable to microbial growth.
Similarly, the application of pressure waterfalls It ensures that air always flows from cleaner areas to the areas of less criticality, avoiding any setback that could compromise the integrity of the productive environment.
Architectural finishes
Architectural finishes in pharmaceutical facilities must be designed with materials and constructive solutions that support the cleaning and microbiological control of the environment. For this, smooth, not porous and resistant surfaces are used to cleaning and disinfection agents, which facilitates maintenance and avoids degradation with use. Similarly, rounded corners (coving) and adequate sealed reduces dust accumulation or biocaring points, reinforcing area hygiene.
The use of Automatic or interlock doors It allows to control the entry and exit of personnel and materials, minimizing the simultaneous opening of locks and guaranteeing the preservation of environmental conditions in classified areas.
Microbiological control
Microbiological control in pharmaceutical facilities is supported by Environmental Monitoring Programs That include methods such as sedimentation plates, active air sampling and direct surface contact, which allows detecting the presence of pollutants in different phases of the process. In critical areas, such as aseptic filling lines, this control should be reinforced by continuous monitoring in real time, thus guaranteeing that any deviation is immediately identified and corrective measures are applied before compromising the quality of the product.
Cross contamination prevention
Cross pollution prevention requires a comprehensive strategy that combines design measures, technology and validated procedures. First, the Segregation of production areas For products with greater risk, such as beta -lactam antibiotics or biological products, in order to avoid any possibility of unwanted transfer. Also, the Implementation of containment technologies, as insulators or rabs systems, reinforces security in critical operations by creating physical barriers between the product and the environment.
The rigorous validation of cleaning and decontamination procedures ensures, on the other hand, that each area or equipment recovers its initial conditions after each use, guaranteeing the protection of the product, the personnel and the patient.
Personnel management and operational practices
The correct management of personnel and operational practices is a decisive factor in pollution control. This implies strict compliance with GMP clothing standards, adapted to the degree of classification of the area, as well as the use of personnel locks that regulate entries and exits to maintain environmental integrity. In addition, the Implementation of continuous training programs, to ensure that all personnel involved in production and support know and consistently apply the hygiene and manipulation practices required by regulations.
Emerging technologies
Emerging technologies are transforming the way in which contamination control in pharmaceutical facilities is managed. The introduction of continuous monitoring systems of particles and microorganisms, together with the integration of IoT sensors and Digital platforms, allows you to have real time data to anticipate deviations and apply corrective measures immediately. This evolution towards predictive and digitized control reinforces the ability of plants to Maintain safe and validated environments, aligned with the most demanding regulatory standards for industry challenges in the digital age.
Flexibility and scalability
The design of GMP facilities cannot be thought solely based on current production needs. The constant evolution of the industry, with the arrival of New types of medications, regulatory changes, Short life cycles and Customized demandsN, requires facilities capable of adapting quickly and safely.
Modular production and versatile rooms
Modular production and multipurpose rooms represent a Strategic solution to provide the pharmaceutical facilities with greater flexibility and adaptation capacity.
The use of prefabricated production modules allows to reconfigure spaces according to new product lines or demand changes, reducing implementation times and associated costs. Similarly, multipurpose rooms, equipped with furniture and mobile equipment, offer the possibility of performing different processes in the same environment under controlled conditions, provided there is adequate validation and temporal segregation.
To all this, the incorporation of single -use systems, which facilitate campaign changes by minimizing the need for cleaning and validation between lots, thus increasing efficiency and reducing cross contamination risks.
Production climbing
Production climbing It must be considered from the plant design phase. Critical areas must have the ability to house both pilot equipment and large -scale production equipment, without compromising the classification of clean areas. In the same way, it is advisable additional capacity for future expansions, avoiding expensive subsequent modifications. This forecast also includes the dimensioning of technical spaces and maintenance corridors that facilitate the installation of new equipment without interrupting the ongoing operations.
Adaptation to new products and technologies
With the growing demand for advanced therapies (ATMPs), biological and personalized medications, facilities must be versatile enough to incorporate innovative processes and smaller -scale lots. For this, it is useful to include flexible support areas such as quality control laboratories, stores with different conservation conditions and spaces designed to integrate new automation or digitalization systems, such as Manufacturing Execution Systems (Mes) The IoT platforms.
Regulatory compliance throughout the life cycle
Each modification or expansion It must be managed under a validated change control system, guaranteeing that design updates are documented in the Design Qualification (DQ) and in the regulatory records. In this way, it is ensured that the plant maintains its validated status and complies with international regulations, even in processes of expansion or technological adaptation.
Resource optimization
Policive spaces and vertical design solutions, such as facilities at various levels that separate flows of materials and personnel, allow maximizing the use of the built area and reduce initial investment costs. This efficiency not only provides economic value, but contributes to project sustainability by reducing energy and resources consumption during plant operation.
Documentation and regulatory compliance
The design of pharmaceutical facilities must be supported from the beginning by a robust documentary strategy that ensures the traceability of decisions made, he Compliance with international standards and the Preparation against regulatory inspections. The documentation not only supports the validation of the facilities, but also constitutes evidence of control and quality against agencies such as EMA, FDA, MHRA U WHO.
Key aspects:
User Requirements Specifications (USE)
Initial document that includes user needs: production capabilities, cleaning levels, critical profits, security criteria and applicable regulations. It must be clear, verifiable and aligned with the business and regulatory objectives.
Design qualification (DQ)
Documentary validation that the proposed design complies with the US and the GMP regulations. It involves the multidisciplinary review (engineering, quality, production, security) before approving the step to construction.
Validation Master Plan (VMP)
Strategic document that defines the validation policy of the plant, the sequence of activities, responsibilities and acceptance criteria. It includes the strategy to qualify facilities, support systems (HVAC, water, gases ...), computerized process equipment and systems.
Changing Management (Change Control)
Any modification in design, construction or implementation must be formally evaluated under a change control procedure. This system ensures that impacts in quality, safety or compliance are identified and managed before implementation.
International regulatory compliance
The design must contemplate from the beginning the requirements of multiple agencies, especially if the plant will produce for export, such as:
- EU GMP (including annexes such as Annex 1 and Annex 11).
- 21 CR Part 210/211 and part 11 of the FDA.
- ICH Q9/Q10 on Risk Management and Pharmaceutical Quality Systems.
- ISPE and WHO TRS Guide.
Preparation for audits and inspections.
The design and validation documentation must be organized, accessible and updated. Having a regulatory data facilitates responding to auditors and demonstrates control over the installation life cycle.
Documentation digitalization
Increasingly, companies migrate to electronic document management systems (EQMS, EDMS), which improves traceability and reduces risks associated with paper documents. These systems must also comply with regulations such as 21 CFR Part 11 in terms of registers and electronic signatures.
In our next installment we will explore the second part of this article, in which we will deepen the advanced aspects of the GMP design, covering key elements such as the Ergonomics and staff safety, the Critical Profit Management, the Maintainability and accessibility of equipment, as well as the Current challenges and emerging trends that will mark the future of the pharmaceutical industry. It will be an opportunity to understand how these dimensions complement the foundations seen in this first part and, together, they build a comprehensive approach that allows to design robust, efficient, sustainable and prepared facilities to successfully overcome regulatory audits and market challenges.